Prosecution Insights
Last updated: April 19, 2026
Application No. 18/224,080

METHODS AND ASSEMBLIES FOR DEPLOYING BILIARY STENTS

Non-Final OA §102§103
Filed
Jul 20, 2023
Examiner
SPENCER, MAXIMILIAN TOBIAS
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Endo Gi Medical Ltd.
OA Round
1 (Non-Final)
33%
Grant Probability
At Risk
1-2
OA Rounds
2y 10m
To Grant
65%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allow Rate
20 granted / 61 resolved
-37.2% vs TC avg
Strong +32% interview lift
Without
With
+32.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
49 currently pending
Career history
110
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
61.8%
+21.8% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
18.7%
-21.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 61 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 51, 54-56, and 58 are pending and examined below. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 51 and 58 is/are rejected under 35 U.S.C. 102(2) as being anticipated by WO 2017/109783 (Einav) Regarding claim 51, Einav discloses a method for deploying a biliary stent in a lumen of a human body, using a guidewire arranged such that a distal end-section thereof is disposed within the body lumen and a proximal end-section thereof is outside the body (see Figs. 1 and 2), the method comprising: a. providing a stent-deployment assembly (Fig. 2) comprising: i. a biliary stent (Fig. 2, 52,54); and ii. an elongated stent-conveyance tube (Fig. 2, 22) comprising a guidewire- retaining segment (Fig. 4, 122) that includes (i) respective distal and proximal apertures defining a guidewire-path therethrough (Fig. 2, wherein distal and proximal ends of 22 defines a guidewire path), and (ii) a lengthways laterally-breachable portion (Fig. 2, wherein the slit 27 corresponds to a lengthways laterally-breachable portion) b. distally advancing the stent-deployment assembly along the guidewire into a body lumen of a human subject in a stent-advancement configuration (Page 17, Lines 4-6, wherein “apparatus 20 is advanced into a body of the subject along the guidewire 12) (i) the guidewire passes through the respective apertures so as to interiorly traverse the guidewire-retaining segment (Page 16, Line 24 to Page 17, Line 5, wherein the guidewire 12 interiorly traverses guide tube 22), and (ii) the stent is arranged to surround a stent-conveyance tube segment that is proximally displaced from the guidewire-retaining segment (see Figs. 2 and 4, wherein stents 52, 54 are surround 22 and are proximally displaced from 122); and c. when the stent is disposed, in the stent-advancement configuration, at a target deployment location within the lumen, withdrawing the stent- conveyance tube a proximal-direction (Page 17, “guide tube 22 is pulled proximally”) so as to cause the guidewire to breach the laterally-breachable portion of the guidewire-retaining segment (Page 17, Line 27, wherein “guidewire 12 slides through slit 28 of guide tube 22” corresponds to cause the guidewire to breach the laterally-breachable portion of the guidewire-retaining segment) and decouple the guidewire from the tube without longitudinal displacement of the guidewire (Page 17, wherein “center within a lumen of the guide tube corresponds to decouple the guidewire from the tube without longitudinal displacement of the guidewire). Regarding claim 58, Einav further discloses wherein the stent is deployed in the lumen (Page 18, Lines 9-11, wherein “allows for deployment of second stent 54” corresponds to the stent is deployed in the lumen) without manipulating the guidewire (Page 18, Lines 9-11, wherein “while maintaining guidewire 12 within lumen 4” corresponds to the without manipulating the guidewire) Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 54 and 55 is/are rejected under 35 U.S.C. 103 as being unpatentable over WO 2017/109783 (Einav) in view of US 2005/0085891 (Goto) Regarding claim 54, Einav doesn't explicitly teach or disclose a pushing tube or a proximally withdrawable locking mechanism. Goto discloses a stent-deployment assembly (Fig. 1) additionally comprising: (i) a pushing tube (Fig. 15C, pusher tube 60) and a proximally withdrawable locking mechanism (Fig. 1, 21) and (ii) the proximally withdrawable locking mechanism engages the stent with the pushing tube (¶0050, wherein 21 engages with depression 17 of stent 14) and is effective to maintain a position of the stent relative to the tube when the assembly is advanced along the guidewire in the stent-advancement configuration (¶0051, wherein 14 fixes position of stent on the tube). It would have been obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention to modify the stent deployment assembly of Einav with a pushing tube and a proximally withdrawable locking mechanism, as taught by Goto, in order to more easily manipulate the position of the stent. Regarding claim 55, Einav discloses a method comprising a stent conveyance tube (see rejection of claim 51) but doesn't explicitly teach or disclose wherein proximally withdrawing the stent-conveyance tube disengages the proximally- withdrawable locking mechanism. Goto discloses wherein proximally withdrawing the stent-conveyance tube (¶0051, wherein “when the guide catheter 11 is pulled off the stent 14” corresponds to proximally withdrawing the stent-conveyance tube) disengages the proximally- withdrawable locking mechanism (¶0051, wherein “the engagement member 21 moves out of the engagement depression” corresponds to disengaging the proximally withdrawable locking mechanism) It would have been obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention to modify the method of Einav with a locking mechanism that disengages when proximally withdrawn, as taught by Goto, in order to complications when placing the stent. Claim(s) 56 is/are rejected under 35 U.S.C. 103 as being unpatentable over WO 2017/109783 (Einav) in view of US 2018/0344493 (Epstein) Regarding claim 56, Einav discloses a stent conveyance tube (see rejection of claim 51 above) and a guidewire-retaining segment (Fig. 4, 122) but doesn't explicitly teach or disclose wherein a segment of the stent-conveyance tube proximally abutting the guidewire- retaining segment has a smaller diameter than does the guidewire-retaining segment. Epstein discloses wherein a segment of the stent-conveyance tube proximally abutting (see annotated Fig. 1 below) the guidewire- retaining segment has a smaller diameter (see annotated Fig. 5 below wherein the diameter of the stent-conveyance tube is indicated with a dotted arrow) than does the guidewire-retaining segment (see annotated Fig. 5 below, wherein the diameter of the guide-wire retaining segment is indicated with a solid arrow) PNG media_image1.png 415 830 media_image1.png Greyscale It would have been obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention to modify the diameter of the guidewire-retaining segment to be larger than segment distally abutting it, in order to navigate through regions of high resistance more easily. Conclusion Included below is relevant prior art that was considered but not relied upon for this office action: US 2011/0087234 – discloses a method and apparatus for introducing multiple medical devices into a lumen US 4,874,274 – discloses a medical tool introduction canula with a longitudinal slit in the proximal end US 6,346, 093 – discloses a biliary catheter with a common distal lumen Any inquiry concerning this communication or earlier communications from the examiner should be directed to MAXIMILIAN TOBIAS SPENCER whose telephone number is (571)272-8382. The examiner can normally be reached M-F 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jerrah Edwards can be reached on 408.918.7557. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MAXIMILIAN TOBIAS SPENCER/Examiner, Art Unit 3774 /JERRAH EDWARDS/Supervisory Patent Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Jul 20, 2023
Application Filed
Jan 07, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12508010
Medical Devices for Repairing Perforations in Tissue, Methods of Manufacturing Medical Devices, and Methods of Implanting a Medical Device
2y 5m to grant Granted Dec 30, 2025
Patent 12370066
DEVICE AND METHOD FOR RESISTIVE TORQUE CONTROL IN A MAGNETORHEOLOGICAL ACTUATOR USING A RECOVERY PULSE
2y 5m to grant Granted Jul 29, 2025
Patent 12303408
POWERED FINGER WITH LOCKING RACK MECHANISM
2y 5m to grant Granted May 20, 2025
Patent 12263102
PROSTHETIC FOOT WITH VARIABLE STIFFNESS ANKLE
2y 5m to grant Granted Apr 01, 2025
Patent 12201538
EXPANDING TIBIAL STEM
2y 5m to grant Granted Jan 21, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
33%
Grant Probability
65%
With Interview (+32.3%)
2y 10m
Median Time to Grant
Low
PTA Risk
Based on 61 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month